EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Franklin Resources Inc.

Franklin Resources Inc. grew its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 11.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,640,651 shares of the company's stock after purchasing an additional 488,206 shares during the quarter. Franklin Resources Inc. owned about 9.86% of EyePoint Pharmaceuticals worth $107,245,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of EYPT. Deutsche Bank AG boosted its holdings in EyePoint Pharmaceuticals by 4.0% in the 3rd quarter. Deutsche Bank AG now owns 21,764 shares of the company's stock worth $174,000 after buying an additional 830 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of EyePoint Pharmaceuticals by 6.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,584 shares of the company's stock valued at $360,000 after purchasing an additional 882 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter valued at $27,000. Toth Financial Advisory Corp lifted its holdings in EyePoint Pharmaceuticals by 42.9% during the 4th quarter. Toth Financial Advisory Corp now owns 5,000 shares of the company's stock worth $116,000 after purchasing an additional 1,500 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in EyePoint Pharmaceuticals in the 4th quarter worth about $94,000. Hedge funds and other institutional investors own 99.41% of the company's stock.

Insider Buying and Selling at EyePoint Pharmaceuticals

In other news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $12.65, for a total value of $147,056.25. Following the transaction, the director now owns 5,550 shares in the company, valued at $70,207.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director David R. Guyer sold 11,625 shares of the company's stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $12.65, for a total transaction of $147,056.25. Following the completion of the sale, the director now directly owns 5,550 shares in the company, valued at approximately $70,207.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Cormorant Asset Management, Lp purchased 581,765 shares of the company's stock in a transaction on Thursday, April 18th. The shares were purchased at an average cost of $18.03 per share, with a total value of $10,489,222.95. Following the transaction, the insider now directly owns 7,475,000 shares in the company, valued at $134,774,250. The disclosure for this purchase can be found here. Company insiders own 4.74% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. HC Wainwright decreased their price target on EyePoint Pharmaceuticals from $33.00 to $30.00 and set a "buy" rating on the stock in a research report on Monday, May 13th. Capital One Financial reissued an "overweight" rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. Robert W. Baird lowered their price objective on EyePoint Pharmaceuticals from $46.00 to $38.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 8th. StockNews.com cut EyePoint Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, May 9th. Finally, Mizuho lowered their price target on EyePoint Pharmaceuticals from $39.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, EyePoint Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $33.71.

EyePoint Pharmaceuticals Stock Performance

Shares of NASDAQ EYPT traded up $0.05 during trading hours on Friday, reaching $11.16. 467,833 shares of the stock traded hands, compared to its average volume of 1,110,931. The company's 50-day simple moving average is $17.86 and its two-hundred day simple moving average is $19.47. EyePoint Pharmaceuticals, Inc. has a 52-week low of $5.67 and a 52-week high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative net margin of 157.77% and a negative return on equity of 49.94%. The firm had revenue of $14.03 million for the quarter, compared to the consensus estimate of $8.71 million. During the same period last year, the firm posted ($0.61) earnings per share. On average, sell-side analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.14 EPS for the current fiscal year.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.